Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8381MR)

This product GTTS-WQ8381MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8381MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5330MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ7288MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ7455MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ8306MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ1762MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ4410MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ5118MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14430MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW